EPAR summary for the public
This document is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
What is Quintanrix?
Quintanrix is a vaccine, which is available as a powder and suspension to be made up into a
suspension for injection. It contains the following active substances: toxoids (chemically weakened
toxins) from diphtheria and tetanus, inactivated (killed) Bordetella pertussis (a bacterium that causes whooping cough), parts of the hepatitis B virus andnopolysaccharides (sugars) from the bacterium Haemophilus influenzae type b (‘Hib’, a bacterium that causes meningitis).
What is Quintanrix used for?
Quintanrix is used to vaccinateProductinfants under one year of age against diphtheria, tetanus, pertussis (whooping cough), hepatitis B and ‘invasive’ diseases caused by Hib (such as bacterial meningitis). It is also used as a booster immunisation of young children during the second year of life. It should be used according to official recommendations.